Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides

Mutation-based treatments are a new development in genetic medicine, in which the nature of the mutation dictates the therapeutic strategy. Interest has recently focused on diseases caused by premature termination codons (PTCs). Drugs inducing the readthrough of these PTCs restore the production of...

Full description

Saved in:
Bibliographic Details
Published in:Nucleic acids research 2011-04, Vol.39 (8), p.3350-3362
Main Authors: Floquet, Célia, Deforges, Jules, Rousset, Jean-Pierre, Bidou, Laure
Format: Article
Language:English
Subjects:
Amikacin - pharmacology
Aminoglycosides - pharmacology
Animals
Anti-Bacterial Agents - pharmacology
Antineoplastic Agents - pharmacology
Apoptosis
Biochemistry, Molecular Biology
Cell Line
Cell Line, Tumor
Codon, Nonsense
Genes, p53
Gentamicins - pharmacology
Humans
Life Sciences
Mice
Microbiology and Parasitology
RNA
RNA, Messenger - metabolism
Transcriptional Activation
Tumor Suppressor Protein p53 - biosynthesis
Tumor Suppressor Protein p53 - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mutation-based treatments are a new development in genetic medicine, in which the nature of the mutation dictates the therapeutic strategy. Interest has recently focused on diseases caused by premature termination codons (PTCs). Drugs inducing the readthrough of these PTCs restore the production of a full-length protein. In this study, we explored the possibility of using aminoglycoside antibiotics to induce the production of a full-length functional p53 protein from a gene carrying a PTC. We identified a human cancer cell line containing a PTC, for which high levels of readthrough were obtained in the presence of aminoglycosides. Using these cells, we demonstrated that aminoglycoside treatment stabilized the mutant mRNA, which would otherwise have been degraded by non-sense-mediated decay, resulting in the production of a functional full-length p53 protein. Finally, we showed that aminoglycoside treatment decreased the viability of cancer cells specifically in the presence of nonsense-mutated p53 gene. These results open possibilities of developing promising treatments of cancers linked with non-sense mutations in tumor suppressor genes. They show that molecules designed to induce stop-codon readthrough can be used to inhibit tumor growth and offer a rational basis for developing new personalized strategies that could diversify the existing arsenal of cancer therapies.
ISSN:0305-1048
1362-4962
DOI:10.1093/nar/gkq1277